Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis - Top-Institutions - MDSpire

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis

  • By

  • Yuanlan Yang

  • Yujun Li

  • Jishi Wang

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    European Society for Blood and Marrow Transplantation (EBMT)
    European Society for Blood and Marrow Transplantation (EBMT)

    N/A, N/A

    Key Differentiators

    • Hematology

  • #2

    People’s Hospital of Qianxinan Buyi and Miao Autonomous Prefecture
    People’s Hospital of Qianxinan Buyi and Miao Autonomous Prefecture

    Qianxinan, Guizhou

    Key Differentiators

    • Hematology

  • #3

    Nagoya University Graduate School of Medicine
    Nagoya University Graduate School of Medicine

    Nagoya, Aichi

    Key Differentiators

    • Hematology

  • #4

    Japan Association of Spine Surgeons With Ambition
    Japan Association of Spine Surgeons With Ambition

    N/A, N/A

    Key Differentiators

    • Hematology

  • #5

    Hospital Clínico of Valencia
    Hospital Clínico of Valencia

    Valencia, Valencia

    Key Differentiators

    • Hematology

Original Source(s)

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis

  • by Yuanlan Yang, Yujun Li, Jishi Wang

  • May 28, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity